Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a higher radiation dose beat cervical cancer without more harm?

NCT ID NCT02880007

Disease control Sponsor: Institut de Cancérologie de Lorraine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

This trial tests whether giving a higher radiation dose during brachytherapy, a type of internal radiation, can improve local control in patients with locally advanced cervical cancer. Participants receive standard external beam radiation and chemotherapy, plus a boosted brachytherapy dose aimed at the tumor. The goal is to increase the two-year local control rate from about 71% to nearly 87% while keeping severe complications below 6.5%. The study includes adults with stage IB2, II, or III cervical cancer who are eligible for curative treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
External beam radiation therapy, pulsed dose rate brachytherapy, and cisplatin chemotherapy
What this could lead to
If successful, this could improve local tumor control for cervical cancer patients, potentially increasing the chance of keeping the disease in check without raising serious side effects.
What could go wrong
This is a phase II trial with a modest number of participants, so results may not hold in larger groups. Higher radiation doses also carry a risk of increased complications, which the trial aims to keep below a set threshold.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

48 people

The number who actually took part.

Started

Jun 2011

Finished

Jul 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * primitive cervical cancer * adenocarcinoma histologically advanced * IB2, II and III stage * curative treatment * indication of utero-vaginal brachytherapy with external radiotherapy * non-metastatic tumor and life expectancy \> 6 months * patient informed and follow possible * performance status ≤ 2 * unplanned surgery * age ≥ 18 years old * ability to provide written informed consent before the start of any study specific procedures Exclusion Criteria: * primitive endometrial cancer * other diseases * carcinoma in situ and stages ≤ B * distant metastases * history of pelvic irradiation or a first pelvic cancer * contraindication to MRI * history of subtotal or total hysterectomy * pregnant or breast feeding females * inability to support low dose rate continuous brachytherapy or pulsed flow * person in emergencies * person unable to give personally consent * patient participating in another clinical research except in case of local recurrence or observational research

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical adenocarcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical adenocarcinoma cervical cancer cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical adenocarcinoma Stage IB cervical cancer Stage II cervical cancer Stage III cervical cancer

Contacts and locations

Locations

  • CHRU Tours - Hôpital Bretonneau

    Tours, 37044, France

  • CHU de Besançon

    Besançon, 25030, France

  • Centre Claudius Regaud

    Toulouse, 31052, France

  • Centre Georges-François Leclerc

    Dijon, 21079, France

  • Centre Léon Bérard

    Lyon, 69373, France

  • Centre Paul Strauss

    Strasbourg, 67065, France

  • Centre Val d'Aurelle

    Montpellier, 34298, France

  • Institut Bergonié

    Bordeaux, 33076, France

  • Institut de Cancérologie de Lorraine

    Vandœuvre-lès-Nancy, 54519, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.